Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers
| Status: | Completed |
|---|---|
| Conditions: | Chronic Pain, Migraine Headaches |
| Therapuetic Areas: | Musculoskeletal, Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | October 2011 |
| End Date: | February 2013 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Randomized, Placebo Controlled, Double-Blind, Third Party Open, Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Female Adult Volunteers
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and
pharmacodynamics of PF-04427429 in healthy women.
Inclusion Criteria:
- Generally healthy women, of non-child bearing potential, between the ages of 18 and
65 years, inclusive. Healthy is defined as no clinically relevant abnormalities
identified by a detailed medical history, full physical examination, including blood
pressure and pulse rate measurement, 12-lead ECG or clinical laboratory tests.
- Body Mass Index (BMI) of 17.5 to 35.0 kg/m2; and a total body weight between 50 kg
(110 lbs) and 120 kg (265 lbs) inclusive.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, hepatic, psychiatric, or neurologic, disease. Subjects
with asymptomatic, seasonal allergies at the time of dosing will not be excluded.
- Women of childbearing potential.
- History or diagnosis of ocular disease or conditions that would confound the
assessment of ocular safety, such as diabetic retinopathy, uveitis, severe wet or dry
AMD.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials